20/20 Biolabs, Inc. Common Stock
AIDX
Get informed when a big investor buys or sells
+ FollowMarket Cap$6.86M
Close$
Share Statistics
| Market cap | $6.86 Million |
|---|---|
| Enterprise Value | $3.35 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.6 |
| Beta | 1.54 |
| Outstanding Shares | 10,790,722 |
Return
| Return on Equity | -428.70% |
|---|---|
| Return on Assets | -113.47% |
| Return on Invested Capital | -132.61% |
Valuation & Multiples
| P/E Ratio | -0.74 |
|---|---|
| PEG | -0.61 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 1.65 |
| Enterprise Value to EBIT | -0.71 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.31 |
| Debt to Equity | 0.64 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 2, 2026
EPS Estimate
$-0.12
Average shareholder expectationRevenue Estimate
$636,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 5.01%▲ 2.18% |
|---|---|
| Total Invested | $297,121▼ 47.39% |
| Investors Holding | 15▲ 8.00% |
ESG Score
No data
About 20/20 Biolabs, Inc. Common Stock
13 employees
CEO: Jonathan Cohen 20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offer...